Literature DB >> 28752492

Pulmonary Involvement in Systemic Vasculitis.

Luis Felipe Flores-Suárez1, Marco A Alba2, Heidegger Mateos-Toledo3, Natllely Ruiz4.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to describe the most relevant advances concerning lung involvement in the ANCA-associated vasculitides (excluding eosinophilic granulomatosis with polyangiitis which may have different disease mechanisms). Focus is on pathophysiology, recent important imagenological procedures, treatment, and outcome. RECENT
FINDINGS: Emerging information exists on potential newly investigated diagnostic procedures (v.g. transbronchial cryobiopsies), detailed tomographic abnormalities, the potential favorable role of rituximab and the still uncertain one of plasma exchange in the treatment, and the increasing description of interstitial lung disease. Survival is reduced in case of both, diffuse alveolar hemorrhage and diffuse parenchymal disease. There is the need to expand the knowledge concerning better long-term treatment options with specific regimes, and to incorporate other measures regarding integral treatment in patients afflicted with lung involvement these maladies, as the outcome seems adverse in this scenario.

Entities:  

Keywords:  ANCA-associated vasculitis; Granulomatosis with polyangiitis; Interstitial lung disease; Lung; Microscopic polyangiitis; Pulmonary vasculitis

Mesh:

Substances:

Year:  2017        PMID: 28752492     DOI: 10.1007/s11926-017-0682-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  48 in total

1.  Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity?

Authors:  A Mueller; K Holl-Ulrich; P Lamprecht; W L Gross
Journal:  Rheumatology (Oxford)       Date:  2008-05-31       Impact factor: 7.580

2.  Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis.

Authors:  Masaru Ando; Eishi Miyazaki; Toshihiro Ishii; Yutaka Mukai; Mari Yamasue; Hideaki Fujisaki; Takeo Ito; Shin-ichi Nureki; Toshihide Kumamoto
Journal:  Respir Med       Date:  2013-02-19       Impact factor: 3.415

Review 3.  Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  Richard A Watts; Alfred Mahr; Aladdin J Mohammad; Paul Gatenby; Neil Basu; Luis Felipe Flores-Suárez
Journal:  Nephrol Dial Transplant       Date:  2015-04       Impact factor: 5.992

4.  Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes.

Authors:  Rodrigo Cartin-Ceba; Luis Diaz-Caballero; Mazen O Al-Qadi; Stavros Tryfon; Fernando C Fervenza; Steven R Ytterberg; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995

5.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

6.  Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.

Authors:  Aleeza J Roth; Joshua D Ooi; Jacob J Hess; Mirjan M van Timmeren; Elisabeth A Berg; Caroline E Poulton; JulieAnne McGregor; Madelyn Burkart; Susan L Hogan; Yichun Hu; Witold Winnik; Patrick H Nachman; Coen A Stegeman; John Niles; Peter Heeringa; A Richard Kitching; Stephen Holdsworth; J Charles Jennette; Gloria A Preston; Ronald J Falk
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

7.  ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process.

Authors:  N J Holden; J M Williams; M D Morgan; A Challa; J Gordon; R J Pepper; A D Salama; L Harper; C O S Savage
Journal:  Ann Rheum Dis       Date:  2011-08-21       Impact factor: 19.103

8.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kirsten De Groot; Niels Rasmussen; Paul A Bacon; Jan Willem Cohen Tervaert; Conleth Feighery; Gina Gregorini; Wolfgang L Gross; Raashid Luqmani; David R W Jayne
Journal:  Arthritis Rheum       Date:  2005-08

9.  Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.

Authors:  Julia U Holle; Christin Dubrau; Karen Herlyn; Martin Heller; Petra Ambrosch; Bernhard Noelle; Eva Reinhold-Keller; Wolfgang L Gross
Journal:  Ann Rheum Dis       Date:  2011-10-21       Impact factor: 19.103

10.  Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.

Authors:  Satoshi Ikeda; Machiko Arita; Kenta Misaki; Yumiko Kashiwagi; Yuhei Ito; Hirotaka Yamada; Machiko Hotta; Akihiro Nishiyama; Akihiro Ito; Maki Noyama; Takashi Koyama; Kenji Notohara; Tadashi Ishida
Journal:  BMC Pulm Med       Date:  2015-07-30       Impact factor: 3.317

View more
  3 in total

Review 1.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

2.  Late restoration of renal function in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation.

Authors:  Tian-Tian Ma; Yi-Ran Liu; Min Chen; Ming-Hui Zhao
Journal:  Clin Rheumatol       Date:  2018-04-20       Impact factor: 2.980

3.  Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: a study of 124 Chinese patients.

Authors:  Jia Shi; Qing Shen; Xue-Mei Chen; Xiao-Gang Du
Journal:  BMC Nephrol       Date:  2019-09-02       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.